Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Change in Account Payables: 2010-2025

Historic Change in Account Payables for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $6.3 million.

  • Arrowhead Pharmaceuticals' Change in Account Payables fell 84.79% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 213.55%. This contributed to the annual value of $6.3 million for FY2025, which is 213.55% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Change in Account Payables of $6.3 million as of FY2025, which was up 213.55% from -$5.5 million recorded in FY2024.
  • In the past 5 years, Arrowhead Pharmaceuticals' Change in Account Payables registered a high of $33.0 million during FY2023, and its lowest value of -$6.6 million during FY2022.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median Change in Account Payables value was $6.3 million (recorded in 2025), while the average stood at $11.2 million.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Change in Account Payables crashed by 350.72% in 2022, and later soared by 600.80% in 2023.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Change in Account Payables (Yearly) stood at $2.6 million in 2021, then crashed by 350.72% to -$6.6 million in 2022, then soared by 600.80% to $33.0 million in 2023, then slumped by 116.78% to -$5.5 million in 2024, then surged by 213.55% to $6.3 million in 2025.